Tempest Therapeutics, Inc. TPST
0.40 USD +0.02 (+6.09%)
At closeNov 11, 2026, 4:00 PM EST
0.38 -0.02 -4.51%
After hours · Nov 11, 4:00 PM ET
0.379 Day range 0.4766
0.337 52-week range 9.75
- YTD
- -86.17%
- 1 year
- -95.87%
News
benzinga.com Tempest Therapeutics Exercises Option To License Senlang’s CD7-Targeted Lentiviral Outside China empest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
benzinga.com Tempest Therapeutics Files Prospectus Registering Resale Of Up To 9,534,164 Shares Of Common Stock Up to 9,534,164 Shares of Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus, referred to as the selling stockholders,…
benzinga.com HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7 HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million. Akanda (NASDAQ:AKAN) stock rose 15.07%…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday's after-market session. The market value of their outstanding shares is at $8.3 million. Alaunos…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
benzinga.com Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action? Shares of Tempest Therapeutics Inc (NASDAQ: TPST) are trading sharply higher Wednesday morning as investors respond positively to a strategic agreement expanding the company's next-generation cell…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
benzinga.com Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
benzinga.com Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why Tempest Therapeutics shares soared 66.53% after hours Tuesday following an exclusive option agreement expanding its in vivo CAR-T pipeline.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
- benzinga.com Tempest Therapeutics Commences ~$2.5M Offering Of 3.106M Common Shares At $0.805 Per Share Tempest Therapeutics, Inc. (Nasdaq: TPST) (the "Company"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease,…
benzinga.com Tempest Therapeutics Secures $50M Equity Purchase Agreement With Lincoln Park Capital On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the
benzinga.com Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 83.57 percent increase over losses…- benzinga.com Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026 Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell…
benzinga.com Tempest Unveils Next-Gen In Vivo CAR-T Platform; To Advance TPST-4003 Into Q4 2026 Trial In MG, MS Patients Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approachLead candidate TPST-4003 combines…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. Mobile-health Network…
benzinga.com Tempest Therapeutics Nicholas Maestas Resigns As CFO Effective June 5, 2026; Appoints Justin Trojanowski As Principal Financial Officer Effective June 5, 2026 https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526257684/d91703d8k.htm- benzinga.com Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.28) by 78.57 percent. This is a 84.18 percent increase over losses…
- benzinga.com Tempest Therapeutics To Present Most Recent Clinical Data From Lead Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy Product Candidate, TPST-2003, At ISCT Scientific Annual Meeting Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure…
- benzinga.com Tempest Therapeutics Reaches Milestone In TPST-2003 Manufacturing Process TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth and durability in patients with relapsed/refractory multiple myeloma ("rrMM") through a parallel…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(3.52) by 82.39 percent. This is a 87.77 percent increase over losses…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Tempest Therapeutics Announces Up To $6M Private Placement; Warrants Will Have Exercise Price Of $2.16/Share Tempest Therapeutics has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to…
- benzinga.com Tempest Therapeutics Selects Cincinnati Children's AGCTC As Lead Contract Development And Manufacturing Partner To Conduct Formal Technology Transfer Of TPST-2003 For Treatment Of rrMM Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned…
- benzinga.com Tempest Therapeutics Announces Clinical Data From Ongoing REDEEM-1 Phase 1/2a Trial Evaluating TPST-2003, CD19/BCMA Dual-Targeting CAR-T Therapy 100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from Neutral to Buy and announces $11 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Tempest Therapeutics Announces ~$4.25M Offering Of 1.2M Common Stock, 1.2M Warrants At $3.625/Share Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast 
benzinga.com Why Tempest Therapeutics (TPST) Stock Is Down 45% Today Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.- benzinga.com Tempest Announces Matt Angel To Assume Role Of President And CEO; Stephen Brady To Assume Role Of Chairman Of The Board Of Directors Upon Closing Of The Acquisition Matt Angel, Ph.D.Dr. Matt Angel is an experienced biotechnology executive with expertise in leading lean cell therapy companies. Dr. Angel led Brooklyn Immunotherapeutics (NASDAQ:BTX) as CEO from…
- benzinga.com UPDATE: Tempest To Acquire Factor's Dual-CAR T Programs In All-Stock Deal, Issuing 8,268,495 Shares; Stockholders Will Be Entitled To Receive 1 Common Stock Warrant For Every Share Of Common Stock Held And Outstanding At A Date Immediately Prior To The Closing; Warrants Will Be Immediately Exercisable With An Initial Exercise Price Equal To $18.48 And Will Expire 5-Years From The Issuance Date Tempest will issue 8,268,495 shares of its common stock, par value $0.001 per share ("Common Stock"), to an affiliate of Factor, equal to 65% of the outstanding shares of Common Stock, inclusive of…
- benzinga.com Tempest Therapeutics Signs Agreements To Acquire Certain Dual-Targeting Chimeric Antigen Receptor-T Programs From Factor Bioscience Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "the Company"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today…
- benzinga.com Tempest Therapeutics Q3 EPS $(0.79) Beats $(3.27) Estimate Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(3.27) by 75.84 percent. This is a 85.15 percent increase over losses…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session